Aligos Therapeutics Inc 将获2500万美元首付款及最高4.2亿美元里程碑款项加分层特许权使用费

美股速递
Yesterday

生物制药公司Aligos Therapeutics Inc(ALGS)宣布达成一项重大合作协议,公司将获得2500万美元的预付款。根据协议条款,未来还有望获得总额最高达4.2亿美元的里程碑付款,并附加分层结构的特许权使用费安排。

这笔交易凸显了市场对Aligos Therapeutics研发管线的认可。分层特许权使用费机制意味着公司未来收益将与产品商业化表现直接挂钩,随着销售额增长, royalty 比例将逐步提升。

此次合作将为Aligos Therapeutics提供重要资金支持,加速其创新疗法的研发进程。里程碑付款将分阶段触发,与研发进展和监管审批等关键节点紧密关联。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10